March 6, 2020 / 12:27 PM / a month ago

BRIEF-European Commission Grants Abbvie Marketing Authorization Shortening Maviret Treatment Duration To Eight Weeks

March 6 (Reuters) - Abbvie Inc:

* EUROPEAN COMMISSION GRANTS ABBVIE MARKETING AUTHORIZATION SHORTENING MAVIRET® (GLECAPREVIR/PIBRENTASVIR) TREATMENT DURATION TO EIGHT WEEKS FOR TREATMENT-NAÏVE CHRONIC HCV PATIENTS WITH GENOTYPE 3 AND COMPENSATED CIRRHOSIS

* ABBVIE - MAVIRET NOW AVAILABLE IN EU AS 8-WEEK TREATMENT OPTION FOR TREATMENT-NAÏVE, CHRONIC HCV PATIENTS WITHOUT CIRRHOSIS/WITH COMPENSATED CIRRHOSIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below